Universal-Beteiligungs- und Servicegesellschaft
HRTX icon

Universal-Beteiligungs- und Servicegesellschaft’s Heron Therapeutics HRTX Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-458,766
Closed -$367K – 2155
2026
Q1 		$367K Buy
+458,766
New +$532K ﹤0.01% 1811

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's HRTX Position: Q2 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 458,766 shares — an estimated $367K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in HRTX in Q1 2026 and held it in 1 quarter. The position peaked at $367K in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Universal-Beteiligungs- und Servicegesellschaft reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Universal-Beteiligungs- und Servicegesellschaft sold 458,766 Heron Therapeutics shares in Q2 2026, an estimated $367K.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Heron Therapeutics in Q1 2026 and held it in 1 quarter.
  • Universal-Beteiligungs- und Servicegesellschaft's Heron Therapeutics position peaked at $367K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q2 2026, filed 6 Aug 2026.